STOCK TITAN

Clover Health Investments Corp Stock Price, News & Analysis

CLOV Nasdaq

Welcome to our dedicated page for Clover Health Investments news (Ticker: CLOV), a resource for investors and traders seeking the latest updates and insights on Clover Health Investments stock.

Clover Health Investments Corp (CLOV) operates at the intersection of health insurance and healthcare technology, making its news coverage particularly relevant for investors tracking the Medicare Advantage sector and artificial intelligence applications in medicine. The company's dual focus on insurance operations and physician enablement software creates distinct news categories worth monitoring.

Earnings announcements from Clover Health reveal performance across both business segments: member enrollment trends in Medicare Advantage plans and enterprise adoption of the Counterpart Assistant technology platform. Quarterly reports disclose medical loss ratios, administrative expenses, and Star Ratings trajectory—metrics that directly impact profitability in the Medicare Advantage business model. The company's technology licensing revenue and partnership announcements with health systems provide insight into market validation for AI-powered clinical tools.

Regulatory developments carry particular significance for Clover Health's business model. Changes to Medicare Advantage payment rates, Star Ratings methodologies, or quality measure definitions announced by CMS can materially affect the company's revenue and competitive position. News about healthcare AI regulations, clinical validation requirements, and reimbursement policies for technology-enabled care management services may impact the Counterpart Health business segment.

Research publications and clinical studies demonstrating outcomes associated with the Counterpart Assistant platform represent important credibility markers for the company's value proposition. Announcements of new health system partnerships, platform capabilities, or geographic expansion indicate commercial traction for the physician enablement strategy. Monitor this page for insights into how Clover Health's technology-first approach to Medicare Advantage evolves in a market dominated by traditional health insurance companies.

Rhea-AI Summary

Clover Health (Nasdaq: CLOV) has scheduled its First Quarter 2025 earnings release for Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the quarterly business and financial results.

Investors and interested parties can access the earnings call by dialing 800-274-8461 (U.S. callers) or 203-518-9814 (international callers) using the conference ID: CLOVQ125. A live webcast will be available through the Investor Relations section of Clover Health's website, with the recording remaining accessible for 12 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.61%
Tags
conferences earnings
-
Rhea-AI Summary

Clover Health (NASDAQ: CLOV) has appointed Dr. Shelly Gupta as Chief Medical Officer (CMO) for its Medicare Advantage operations. Dr. Gupta, a family practice physician with over a decade of Medicare Advantage leadership experience, previously held CMO roles at Humana where he led regional MA plans and launched the Humana Healthy Horizons Medicaid plan.

In his new role, Dr. Gupta will oversee Clover's clinical operations, quality initiatives, pharmacy operations, and chronic disease management programs. His responsibilities include:

  • Leveraging data-driven solutions and innovative technology
  • Improving care delivery and member satisfaction
  • Advancing value-based care initiatives
  • Enhancing patient-provider relationships through Clover Assistant technology

At Humana, Dr. Gupta achieved notable results in reducing hospitalizations, enhancing care coordination, and improving health outcomes for members with chronic conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.1%
Tags
management
-
Rhea-AI Summary

Counterpart Health, a subsidiary of Clover Health (Nasdaq: CLOV), has announced a strategic partnership with Google Cloud to integrate Vertex AI Search into its Counterpart Assistant platform. This integration aims to enhance clinical data access and analysis for healthcare providers.

The enhanced Counterpart Assistant now leverages Google Cloud's large language models to synthesize data from over 100 healthcare sources, providing physicians with a comprehensive view of patient histories. Key features include unified search across multiple data sources, AI-generated insights, clinical evidence citations, and contextual data highlighting.

The partnership addresses critical healthcare challenges, including the reported 28 hours weekly that clinicians spend on administrative tasks and an 82% burnout rate. The platform's AI-powered capabilities aim to streamline workflow efficiency, enable earlier diagnoses, and improve chronic disease management while supporting value-based care delivery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.31%
Tags
partnership clinical trial
Rhea-AI Summary

Clover Health (CLOV) reported significant financial improvements for 2024, with full-year Insurance revenue growing 9% to $1.3 billion. The company achieved an Adjusted EBITDA profit of $70 million, marking a $112 million increase year-over-year.

Key financial metrics show substantial progress: GAAP Net loss from continuing operations improved by $164 million year-over-year, while Insurance BER improved to 81.2% for full year 2024 from 86.5% in 2023. Fourth quarter results showed Insurance revenue growth of 9% to $331 million.

For 2025 guidance, Clover Health projects: Average Medicare Advantage membership of 103,000-107,000 (30% growth), Insurance revenue between $1.800-1.875 billion (37% growth), and Adjusted EBITDA profitability between $45-70 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
-
Rhea-AI Summary

Clover Health (Nasdaq: CLOV) has announced its participation in two major upcoming investor conferences in March 2025. Chief Financial Officer Peter Kuipers will be representing the company at both events.

The first engagement is at the 2025 Jefferies Value-Based Healthcare Summit on Monday, March 10, 2025. Following this, Kuipers will present at the 2025 Leerink Global Healthcare Conference on Tuesday, March 11, 2025, at 8:00 a.m. Eastern Time.

For interested parties, a live webcast and replay of the Leerink conference presentation and Q&A session will be available through Clover Health's investor relations website at investors.cloverhealth.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.59%
Tags
conferences
-
Rhea-AI Summary

Clover Health (NASDAQ: CLOV) has announced it will release its fourth quarter and full year 2024 financial results after market close on Thursday, February 27, 2025. The company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the results.

Interested parties can access the call by dialing 800-274-8461 (U.S. callers) or 203-518-9814 (international callers) using the conference ID: CLOVQ424. A live and archived webcast will be available on Clover Health's Investor Relations website for 12 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
conferences earnings
Rhea-AI Summary

Counterpart Health, a subsidiary of Clover Health (NASDAQ: CLOV), has announced a multi-year strategic partnership with Southern Illinois Healthcare (SIH), the largest health system in Southern Illinois. The agreement centers on implementing Counterpart Assistant, an AI-powered platform integrated into SIH's EPIC electronic health record system.

The platform will provide real-time, patient-specific insights to physicians, supporting value-based care delivery without adding administrative complexity. SIH's care teams will receive actionable, data-driven insights directly within their workflows, enabling better patient outcomes while meeting value-based care metrics.

The partnership aims to enhance clinical decision-making, facilitate earlier diagnoses, and improve chronic disease management. Counterpart Assistant, previously known as Clover Assistant, has demonstrated success in improving medication adherence and managing conditions like Diabetes and Chronic Kidney Disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.25%
Tags
none
-
Rhea-AI Summary

Clover Health (CLOV) reported a significant 27% year-over-year growth in its Medicare Advantage membership, surpassing 100,000 members after the recent Annual Election Period. Approximately 95% of members are enrolled in the company's flagship 4-Star PPO plan.

The growth was primarily driven by members switching from other plans, attracted by Clover's robust plan benefits. The 4-Star rating positions the company for an anticipated 5% benchmark increase in payment year 2026. Clover emphasizes its technology-driven approach, using AI to improve clinical outcomes through early identification and management of chronic diseases.

The company plans to balance profitability with strategic investments in growth and technology, leveraging its strong market position and integrated care model. The 4-Star PPO plan has demonstrated top performance across key HEDIS measures, reflecting Clover's commitment to healthcare quality.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
none
-
Rhea-AI Summary

Counterpart Health, a subsidiary of Clover Health (NASDAQ: CLOV), has successfully deployed its Counterpart Assistant technology at Duke Connected Care (DCC). The AI-powered physician enablement platform is now being used by primary care physicians across DCC's network of non-employed physicians.

The cloud-based AI platform integrates with existing electronic health record systems to provide real-time, actionable insights for improved chronic disease management and patient outcomes. DCC, part of Duke University Health System, is a physician-led accountable care organization supporting 2,200 providers and 200,000 patients.

The implementation aims to unify and optimize performance across DCC's network of community practices, particularly benefiting small rural practices that may not have access to advanced EHR systems. The technology, previously known as Clover Assistant, has demonstrated positive impacts on Clinical Quality, Medication Adherence, and management of Diabetes and Chronic Kidney Disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.51%
Tags
none
Rhea-AI Summary

Clover Health (Nasdaq: CLOV) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Andrew Toy will deliver a presentation on Wednesday, January 15, 2025, at 4:30 p.m. Eastern Time. Investors and interested parties can access both the live webcast and replay of the presentation and Q&A session through Clover Health's investor relations website at investors.cloverhealth.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
conferences

FAQ

What is the current stock price of Clover Health Investments (CLOV)?

The current stock price of Clover Health Investments (CLOV) is $2.54 as of January 13, 2026.

What is the market cap of Clover Health Investments (CLOV)?

The market cap of Clover Health Investments (CLOV) is approximately 1.4B.
Clover Health Investments Corp

Nasdaq:CLOV

CLOV Rankings

CLOV Stock Data

1.36B
409.76M
3.88%
35.27%
9.43%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States
JERSEY CITY